anti-TNF-IR phase III To determine the efficacy and safety of ocrelizumab versus placebo in reducing signs and symptoms of rheumatoid arthritis (RA), when used in combination with methotrexate (MTX) or leflunomide given ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Open label, randomized, multicenter study to investigate the efficacy and safety of once-weekly (reduced administration frequency) NeoRecormon® (Epoetin beta) therapy versus thrice weekly NeoRecormon® therapy in anemic patients with metastatic solid tumors receiving chemotherapy (or scheduled to receive chemotherapy) • To demonstrate that epoetin beta (NeoRecormon®) administered 30,000 IU once weekly (q1w) subcutaneously (sc) is at least as efficacious as epoetin beta (NeoRecormon®) administered 10,000 IU sc th...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

ML28337 : Essai de phase 2 randomisé, évaluant l’efficacité du bévacizumab associé à une chimiothérapie standard dans le cadre de la résection tumorale, chez des patientes ayant un cancer épithélial de l’ovaire, des trompes de Fallope ou un carcinome péritonéal primitif non opérable. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] L’objectif de cet essai est d’évaluer l’efficacité du bévacizumab associé à une chimiothérapie par carboplatine et paclitaxel sur la faisabilité d’une résection de la tumeur, chez des patientes ayant ...

• Pays France
• Organes Ovaire, Appareil génital féminin - autres
• Spécialités Chimiothérapie, Chirurgie, Thérapies Ciblées

Étude GO29383 : étude de phase 1b évaluant la sécurité d’emploi d’un traitement associant du MPDL3280A avec obinutuzumab, chez des patients ayant un lymphome folliculaire (LF) ou un lymphome diffus à grandes cellules B (LDGCB) en rechute ou réfractaire. L’objectif de cette étude est d’évaluer la sécurité d’emploi d’un traitement associant du MPDL3280A à l’obinutuzumab, chez des patients ayant un lymphome folliculaire (LF) ou un lymphome diffus à gran...

• Pays France
• Organes Lymphomes non hodgkinien
• Spécialités Immunothérapie - Vaccinothérapie, Thérapies Ciblées

Ensayo randomizado, doble ciego, con doble enmascaramiento, de grupos paralelos para evaluar la eficacia y seguridad de RO4402257 como monoterapia en comparación con la monoterapia de metotrexato para pacientes con artritis reumatoide activa (AR) A randomized, double-blind, double-dummy, parallel group study to determine the efficacy and safety of RO4402257 monotherapy in comparison to methotrexate monotherapy in patients with active rheumatoid arthritis (RA) Evaluar la eficacia de RO4402257 como monoterapia en pacientes adultos con AR activa.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An open-label, multicenter protocol providing pegylated interferon alfa-2a (PEGASYS) as monotherapy or in combination with ribavirin (COPEGUS) for patients with chronic hepatitis C who have participated in previous Roche or Roche partner protocols. Protocollo in aperto, multicentrico, sulla somministrazione di interferone pegilato alfa-2a (PEGASYS) in monoterapia o in combinazione a ribavirina (COPEGUS) in pazienti affetti da epatite cronica C che hanno partecipato a precedenti protocolli di Roche o di un partner di Roche To provide treatment or re-treatment with PEGASYS as monotherapy or in combination with COPEGUS, to patients with CHC who participated in a previous Roche or Roche partner protocol where access to tr...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A clinical study with many of countries and sites participating. This study wants to look into the relationship of the genotype IL28B in patients from all over the world which are suffering from an inflammation of the liver with hepatitis C virus Correlation of Interleukin 28B (IL28B) genotypes rs12979860 (CC vs. TC vs. TT) and rs8099917 (TT vs. GT vs. GG) with liver fibrosis related to CHC

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase II/III, multi-center, randomized, 4-week, double-blind, parallel group, placebo and active-controlled trial of the safety and efficacy of RO4917838 vs. placebo in patients with an acute exacerbation of schizophrenia �Change in Positive and Negative Syndrome Scale (PANSS) total score [ Time Frame: from baseline to Day 28 ] [ Designated as safety issue: No ] � Safety: Incidence adverse events [ Time Frame: 8 week...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomized, multicenter phase II study to explore whether biomarkers correlate with treatment outcome in chemo-naive patients with advanced or recurrent non-squamous non-small cell lung cancer, who receive treatment with bevacizumab (at a dose of either 7.5 mg/kg or 15 mg/kg) in addition to carboplatin based chemotherapy (gemcitabine or paclitaxel) Explore the correlation of biomarkers with response rate as assessed by the investigator (according to RECIST) in patients treated with carboplatin based chemotherapy in combination with 7.5 mg/kg or ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to test if aleglitazar has a positive effect on the heart of patients with Type 2 diabetes and without cardiac disease, looking at the way the heart processes energy and fat To evaluate if aleglitazar improves cardiac energetics, by means of MRS, in uncomplicated T2D patients with no history of CAD, after 6 weeks of treatment

• Pays Aucun
• Organes Aucun
• Spécialités Aucune